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Abstract
There is little doubt that women experience a heightened psychiatric morbidity compared to men. A growing
body of evidence suggests that, for some women, the menopausal transition and early postmenopausal years may
represent a period of vulnerability associated with an increased risk of experiencing symptoms of depression, or for
the development of an episode of major depressive disorder. Recent research has begun to shed some light on
potential mechanisms that influence this vulnerability. At the same time, a number of studies and clinical trials con-
ducted over the past decade have provided important data regarding efficacy and safety of preventative measures
and treatment strategies for midlife women; some of these studies have caused a shift in the current thinking of
how menopausal symptoms should be appropriately managed.
Essentially, most women will progress from premenopausal into postmenopausal years without developing signifi-
cant depressive symptoms. However, those with prior history of depression may face a re-emergence of depression
during this transition while others may experience a first episode of depression in their lives. Here I provide an
overview of what is known about risk factors for depression and the risk posed by the menopausal transition, its
associated symptoms, and the underlying changes in the reproductive hormonal milieu, discussing the evidence
for the occurrence of mood symptoms in midlife women and the challenges that face clinicians and health profes-
sionals who care for this population.
Introduction
Over the past few decades, growing epidemiological and
clinical data support the notion that some, but not
all, women may be at a heightened risk for psychiatric
morbidity (for example, mood and anxiety symptoms,
cognitive complaints) during periods in life that are
associated with reproductive cycle events such as the
postpartum period and the menopausal transition.
These periods are not only marked by extreme hormone
variations but may also be accompanied by the occur-
rence of significant life stressors and changes in perso-
nal, family, and professional responsibilities [1]. The
complexity of the so-called female-specific ‘windows of
vulnerability’ certainly poses a particular challenge to
physicians and other professionals dedicated to women’s
health issues across the life span.
Among these female-specific ‘windows of vulnerabil-
ity’, the menopausal transition constitutes a complex
example: this transition is marked by progressive,
dynamic changes in sex hormones and reproductive
function. At the same time, these changes overlap with
the aging process per se, and with modifications in
metabolism, sexuality, lifestyle behaviors and overall
health [2]. During this period in life, some individuals
may seek medical treatment for a constellation of symp-
toms including vasomotor complaints (VMS; that is, hot
flashes, night sweats), aches and stiff joints, trouble
sleeping, and lack of energy. Others, on a more preven-
tative approach, will inquire about different strategies
(for example, hormonal, non-hormonal, ‘natural’ reme-
dies) to promote a ‘healthier’ transition into postme-
nopausal years. Overall, diagnostic and therapeutic
approaches to symptomatic women during the meno-
pausal transition and postmenopausal years are, or
should be, multifaceted and multidisciplinary in nature
(Figure 1).
Discussion
For decades, the existence of a more causal, direct asso-
ciation between the menopausal transition and the
emergence of depressive symptoms has been the subject
of intense controversy; the question quite often posed
by researchers and clinicians was whether the occur-
rence of menopause-associated depression was caused
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primarily by stressful life events, psychological factors or
by the impact of ovarian hormonal changes. This con-
troversy is illustrated by the array of different theories
and methodological approaches that has guided most of
the research in this field. Some cross-sectional studies
examining the relationship between menopause and
depressive symptoms revealed no association [3-6],
while others showed an increase in depression among
women in the menopausal transition [7,8]. Among var-
ious theories, some have postulated that the occurrence
of depression during this time in life could be in part
modulated by the presence of sleep disruption and/or
the occurrence of VMS. However, a recent study investi-
gated this hypothesis by exploring the interactions
between sleep, vasomotor symptoms and depression
using objective and subjective sleep parameters in mid-
life women with and without depression [9]. Although
depressed women reported poorer sleep quality and effi-
ciency than non-depressed women, the two groups did
not differ with respect to measurements of sleep inter-
ruption. Further, there was, no increased frequency of
nocturnal vasomotor symptoms or awakenings obser-
ved among depressed women, refuting a direct link
hypothesis.
Unlike the cross-sectional studies, most prospective
studies [10-14] have systematically confirmed the meno-
pausal transition as a period of heightened risk for
development of depressive symptoms and/or depression.
The Penn Ovarian Aging Study [12] showed an
increased risk for depressive symptoms during the tran-
sition to menopause followed by a decrease in this risk
in subsequent years (that is, in the postmenopausal per-
iod); the authors also suggested that depression and hor-
mone-related symptoms could share some underlying
mechanisms since history of severe PMS (premenstrual
syndrome), emergence of hot flashes and sleep problems
were independent predictors of depression in this popu-
lation. Two long-term prospective studies followed
women with no history of depression across the meno-
pause transition to examine the risk for new onset of
depression [15,16]. In both studies, a 6-8-year follow-up
of premenopausal women (n = 460 and n = 231, respec-
tively) revealed a significant increased risk (twofold to
fourfold) for developing depression in women as they
entered perimenopause compared to those who
remained premenopausal. Moreover, greater variation of
estradiol and follicle-stimulating hormone (FSH) levels
over the follow-up period appear to be associated with
higher depressive scores and diagnosis of MDD; an indi-
cator that wide fluctuation in hormonal levels, rather
than their absolute levels, may be a contributing factor
to the emergence of depression in biologically vulner-
able women. Other mediators of the risk for depression
in this particular population include ethnicity (higher
Figure 1 Exploring pathways for menopause-associated depression .
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risk in African American, lower risk in Asian popula-
tion), lower education, past history of postpartum blues
or postpartum depression, cigarette smoking, stressful
life events [10-16].
As highlighted above, epidemiologic evidence supports
the ‘critical timing’ hypothesis for the occurrence of
depression, most likely linked to periods of hormone
instability rather then hormone deficiency. Interestingly,
different areas of medicine exploring health-related out-
comes in midlife and aging women seem to agree on
the same notion of a ‘critical timing window’ being asso-
ciated with the menopausal transition and the impor-
tance of proper timing for preventive or therapeutic
strategies. For example, recent evidence from the Study
of Women’s Health Across the Nation (SWAN) showed
changes in processing speed and verbal episodic mem-
ory in women during the menopausal transition, with
memory performance returning to premenopausal levels
in the postmenopausal years [17]. Changes in estrogen
levels during the menopausal transition have also been
associated with heightened risk for adverse cardiovascu-
lar events, including larger adventitial carotid artery dia-
meters, changes in lipids, and increased blood pressure
[18,19].
Evidence from clinical trials supports the concept of a
window of opportunity for hormonal treatment strate-
gies in midlife women, not only for cardiovascular
diseases but also, as further discussed, for menopause-
associated depression. An age-stratified analysis of the
Women’s Health Initiative (WHI) data revealed that sev-
eral of the adverse events initially associated with meno-
pausal hormone therapies (MHTs) in the entire study
population were not evident in the subgroup of younger,
postmenopausal women (between 50 and 59 years of
age) or among those women who had recently transi-
tioned into menopause. In fact, there seemed to be a
cardioprotective effect of MHT (particularly estrogen
based) when hormone therapies were administered to
women within 10 years of the final menstrual period,
possibly because of the fewer preexisting coronary con-
ditions in this subgroup [20]. Further studies are needed
to explore the risks and benefits of hormone therapies
in younger, symptomatic women. Large-scale clinical
studies such as Early versus Late Intervention Trial with
Estrogen (ELITE; NCT00114517) and Kronos Early
Estrogen Prevention Study (KEEPS; NCT00154180) [21]
should be instrumental for the evaluation of ‘critical
timing’ for the use of hormone strategies from a cardio-
vascular and a cognitive perspective.
Antidepressant agents and psychotherapeutic treat-
ments are widely accepted as first-line treatments for
depression across the life span. Indeed, several trials
have documented the efficacy of psychotropic medica-
tions for the alleviation of mood and other menopause-
related symptoms in perimenopausal and postmenopau-
sal women [22-26]. Despite that, preclinical and clinical
evidence supports a possible window of opportunity for
hormonal treatments to manage depressive episodes
associated with the menopausal transition; after all,
estrogen can, in many ways, modulate systems that are
critical for mood and behavior regulation, particularly
through pathways involving monoaminergic neurotrans-
mission (serotonin (5-HT), norepinephrine (NE)) [27].
Estradiol (E2) administration decreases the activity of
monoamine oxidases (MAO-A and MAO-B), which are
enzymes involved in 5-HT degradation; E2 administra-
tion also increases both isoforms of tryptophan hydroxy-
lase (TPH), the rate-limiting enzyme of serotonin
synthesis, resulting in an overall increase in 5-HT synth-
esis and availability. Furthermore, by downregulating
5HT1a autoreceptors and upregulating 5HT2a receptors,
E2 increases the amount of serotonin found in the
synapse and increases the amount available for postsy-
naptic transmission. Similarly, estrogens increase NE
availability by decreasing expression of MAOs and
increasing the activity of tyrosine hydroxylase, the rate-
limiting enzyme in the synthetic pathway of catechola-
mine [28].
Estrogen-based therapies have shown superior antide-
pressant effects compared to placebo when administered
to perimenopausal women [29,30]. The antidepressant
effects of estrogen were observed even in the absence of
concomitant vasomotor symptoms [30]. Older, postme-
nopausal women, however, showed little or no response
to estrogen therapy for the alleviation of depressive
symptoms [31]. Taken together, these observations sug-
gest that estrogen’s antidepressant effect may have a ‘cri-
tical window’ or optimal timing, possibly during the MT
and early postmenopausal years; moreover, the potential
benefits of E2 therapy for the improvement of mood symp-
toms may occur independent from changes/improvement
of vasomotor symptoms.
As symptomatic midlife women may endorse a wide
variety of physical and emotional complaints, physicians
and other health professionals have the challenging task
to disentangle the biological and psychosocial aspects
that could be primarily attributed to (a) the aging pro-
cess per se; (b) the menopausal transition; (c) the emer-
gence of new onset/recurrent depression.
Conclusions
Robust epidemiologic evidence supports the existence of
a ‘window of vulnerability’ for the occurrence of depres-
sion (new onset or recurrent) during the menopausal
transition and early postmenopausal years. Similar to
that observed in other periods in life, antidepressants
and psychotherapies continue to be the treatments of
choice for depression occurring in midlife women.
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Nonetheless, accumulated preclinical and clinical data
support the benefits of estrogen-based therapies to
improve mood and other menopause-related symptoms
during this critical window. As such, estrogen should be
considered part of the treatment armamentarium for
depression, along with other well established benefits
(for example, for vasomotor, sexual and other meno-
pause-related complaints) [32]. Lastly, the use of specific
screening and diagnostic tools for depression in women
[33] should help physicians and health professionals to
improve early detection and clinical management. Ulti-
mately, treatment strategies should be tailored and
incorporate all the resources available to reduce the sig-
nificant burden and functional impairment associated
with depression in women undergoing menopause.
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